On June 4, 2023, Amniotics AB (publ) announced positive experimental results with CogniStem, including high level of biodistribution of the stem cells to the brain tissue. The results opens up for potential applications within Alzheimer's, ALS, and Parkinsons disease. As previously announced, the presentation took place at a symposium on stem cells hosted by Cold Spring Harbor Laboratory (CSHL) on Long Island, New York, June 3, 2023.

The study was an experimental model of hearing loss and altered pain perception, induced by chemotherapy. In the study, intravenous and intraarterial administration of CogniStem, Amniotics' neuro specific stem cell product of neonatal origin, was detected at significant levels in the brain tissue and was coupled with a significant increase of hearing acuity and decrease of neuropathic pain. The next step in the development of CogniStem is continued preclinical development and evaluation, in collaboration with leading researchers at Lund university.